SCHEMBL1556537

SCHEMBL1556537

CC(C)C(N)c1ccc(Cl)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 3/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ ADRB2 P07550 1/20 0.38
▸ HTR2A P28223 3/20 0.36
▸ HTR2C P28335 3/20 0.36
▸ CYP1A2 P05177 3/20 0.36
▸ CYP3A4 P08684 3/20 0.36
▸ CYP2C9 P11712 3/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ SLC6A2 P23975 7/20 0.35
▸ SLC6A4 P31645 7/20 0.35
▸ SLC6A3 Q01959 7/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ S1PR3 Q99500 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15518165 0.85 APP (0.40) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL15496334 0.85 APP (0.40) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL30688937 0.84 ADRB2 (0.50) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL29809135 0.84 ADRB2 (0.50) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL702478 0.84 ADRB2 (0.50) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL960516 0.84 ADRB2 (0.50) APPPSEN1PSEN2APH1BNCSTN
SCHEMBL957890 0.84 ADRB2 (0.50) APPPSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL25385811 0.82 ADRB2 (0.48) APPPSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL25385814 0.82 ADRB2 (0.48) APPPSEN1PSEN2APH1BNCSTN
Hydrochloric Acid SCHEMBL31123022 0.82 ADRB2 (0.48) APPPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120301552-A1 CaSR Antagonist JAPAN TOBACCO INC. (JP) 2012-11-29 — — US disclosed
EP-2308828-A2 CaSR antagonist Japan Tobacco Inc. (JP) 2011-04-13 — — EP disclosed
EP-2189439-A2 CaSR antagonist Japan Tobacco, Inc. (JP) 2010-05-26 — — EP disclosed
US-20090326058-A1 CaSR Antagonist JAPAN TOBACCO INC. (JP) 2009-12-31 — — US disclosed
EP-1619180-B1 CaSR ANTAGONIST JAPAN TOBACCO INC (JP) 2009-12-16 — — EP disclosed
US-20080255042-A1 CaSR Antagonist JAPAN TOBACCO INC. (JP) 2008-10-16 — — US disclosed
US-7304174-B2 CaSR antagonist JAPAN TOBACCO INC. (JP) 2007-12-04 — — US disclosed
EP-1619180-A1 CaSR ANTAGONIST JAPAN TOBACCO INC. (JP) 2006-01-25 — — EP disclosed
US-20050032796-A1 Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis JAPAN TOBACCO INC. 2005-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326058-A1 CaSR Antagonist CASR, CALCR, CALCRL APP 1532/4885PSEN1 1099/4885PSEN2 1102/4885
US-20120301552-A1 CaSR Antagonist CASR, CALCR, CALCRL APP 1532/4885PSEN1 1099/4885PSEN2 1102/4885
US-20080255042-A1 CaSR Antagonist CASR, CALCR, CALCRL APP 1532/4885PSEN1 1099/4885PSEN2 1102/4885
US-20050032796-A1 Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis CASR, CALCR, GRK2 APP 1721/4885PSEN1 1014/4885PSEN2 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback